Chiral C7-functionalized 4-aminoindole compound, and preparation method and application thereof

Through asymmetric Fuker alkylation reaction catalyzed by chiral phosphoric acid, the problem of functionalization of the C7 position of the benzene ring on indole is solved, and efficient and highly selective synthetic chiral C7-functionalized 4-aminoindole compounds are achieved. Enriched the drug library and showed anti-cancer activity.

CN119080761AActive Publication Date: 2024-12-06CHENGDU UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411214507.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-01
Publication Date
2024-12-06
Estimated Expiration
2044-09-01

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently realize the asymmetric functionalization of the benzene ring on indole, especially in the functionalization reaction at C7 position, with high catalyst usage and pre-introduction of activated functional groups, resulting in low reaction efficiency and selectivity.

Method used

Asymmetric Fuker alkylation reaction of 4-aminoindole and benzothiopheneone imine at 0°C to 30°C is carried out to efficiently realize the functional group at the C7 position of indole by para-activation of amino groups. to produce chiral C7-functionalized 4-aminoindole compounds.

Benefits of technology

Achieve high yield and high stereoselective synthesis of chiral C7-functionalized 4-aminoindole compounds containing benzothiophene substructure, providing new candidate molecules for drug development and drug screening, and showing a better Good anti-cancer activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080761A_ABST
    Figure CN119080761A_ABST
Patent Text Reader

Abstract

The invention discloses a chiral C7-functionalized 4-aminoindole compound, and belongs to the technical field of organic chemical synthesis, the compound has a structure as shown in a formula (I); meanwhile, the invention also discloses a preparation method of the compound, which comprises the following steps: dissolving benzothiophene ketimine and 4-aminoindole in an organic solvent, then adding a chiral phosphoric acid catalyst, stirring and reacting at 0-30 DEG C, and after the reaction is finished, separating and purifying to obtain the compound. The compound provided by the invention has a tetra-substituted carbon atom center and also has indole and benzothiophene substructures with pharmacodynamic functional groups, more candidate molecules can be provided for research and development of new drugs and screening of drugs, and the compound shows a better application prospect in the anti-tumor aspect; the preparation method disclosed by the invention has the advantages of novelty, simplicity, simplicity in operation, mild reaction conditions, low catalyst dosage, high yield, high stereoselectivity and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of organic synthesis, and in particular to chiral C7-functionalized 4-aminoindole compounds, preparation methods and applications thereof. Background Art

[0002] Indole structures are widely present in natural and non-natural bioactive molecules and clinical drugs, and are an important source for the development of new drugs. In addition, indole compounds are also widely used in materials science. In particular, chiral C7-functionalized 4-aminoindoles are present in bioactive molecules such as (-)-lyngbyatoxinA, cytoblastin, and teleocidin B. On the other hand, the benzothiophene structure, which is considered to be a dominant structure, is also widely present in many natural products and drug molecules and is widely used in drug design. From the perspective of drug design, organically combining two or more pharmacodynamic functional groups into one molecule may produce unexpected biological activities. Therefore, the synthesis of C7-functionalized 4-aminoindoles containing benzothiophene substructures is of great significance.

[0003] Taking advantage of the intrinsic nucleophilicity of the pyrrole ring on indole, organic chemists have developed a large number of methods to achieve asymmetric functionalization reactions at the C2 and C3 positions of indole. However, due to the relatively low activity of the benzene ring on indole, it is very challenging to achieve asymmetric functionalization of the benzene ring on indole. For example, Pedro's group achieved asymmetric functionalization of the C5 position of indole by introducing a hydroxyl directing group on the benzene ring on indole and utilizing the ortho-activating properties of the hydroxyl group (ACS Catal. 2016, 6, 2689; New J. Chem. 2019, 43, 130). In addition, Zhao's group introduced an amino group at the C4 position of indole and utilized the para-directing effect of the amino group. Although they achieved asymmetric C7 functionalization of 4-aminoindole and activated olefins and carbonyls, the catalyst dosage for these reactions was relatively high and the activated functional group needed to be introduced in advance. Summary of the invention

[0004] One of the purposes of the present invention is to provide a new class of chiral C7-functionalized 4-aminoindole compounds to solve the above problems.

[0005] In order to achieve the above object, the technical scheme of the present invention is as follows: A new type of chiral C7-functionalized 4-aminoindole compound has a structure shown in the following structural formula:

[0006]

[0007] In the above structural formula, R 1The group is a single or multiple substituent, and the substituent is selected from hydrogen, alkyl, alkoxy or halogen; R 2 and R 3 The radicals are independently selected from hydrogen, alkyl, allyl and propargyl.

[0008] The present invention utilizes the para-activation property of the amino group to realize the asymmetric Friedel-Crafts alkylation reaction of 4-aminoindole and benzothiophene imine for the first time. Using chiral phosphoric acid as a catalyst, the reaction can react at the C7 position of indole with very high regioselectivity, and obtain a series of chiral C7-functionalized 4-aminoindole compounds containing benzothiophene substructures in high yield and high stereoselectivity. This type of compound has a tetrasubstituted carbon atom center and contains indole and benzothiophene substructures with pharmacological functional groups, which can provide more candidate molecules for the development of new drugs and drug screening.

[0009] The second object of the present invention is to provide a method for preparing the chiral C7-functionalized 4-aminoindole compound, the technical scheme adopted is: dissolving benzothiophenone imine (II) and 4-aminoindole (III) in an organic solvent, then adding a chiral catalyst, stirring and reacting at 0°C to 30°C, and after the reaction is completed, separating and purifying to obtain a product (I); wherein,

[0010] The benzothiophenone imine (II) has the following structure:

[0011]

[0012] The 4-aminoindole (III) has the following structure:

[0013]

[0014] The synthetic route is:

[0015]

[0016] The present invention adopts the above-mentioned synthesis method to synthesize a series of chiral C7-functionalized 4-aminoindole compounds containing benzothiophene substructures with novel structures.

[0017] As a preferred technical solution: the reaction solvent is selected from one or a mixture of toluene, mesitylene, dichloromethane, chloroform, tetrahydrofuran, ether, acetonitrile, ethanol, methanol, 1,4-dioxane, and chlorobenzene.

[0018] As a further preferred technical solution, the reaction solvent is toluene, which has a higher yield and higher stereoselectivity.

[0019] As a preferred technical solution, the chiral phosphoric acid catalyst is selected from CPA-1, CPA-2, CPA-3, CPA-4 or CPA-5, which has the following structure:

[0020]

[0021] As a further preferred technical solution, the chiral phosphoric acid catalyst is CPA-5, and the reaction yield and enantioselectivity are higher.

[0022] As a preferred technical solution, the amount of the chiral catalyst used is 0.5% to 10% of the molar amount of the thiophene ketimine (II).

[0023] As a further preferred technical solution, the usage of the catalyst is 0.5 mol%, which has lower cost.

[0024] As a preferred technical solution, the reaction temperature is 0°C to 30°C.

[0025] As a further preferred technical solution, the reaction temperature is 0°C, at which temperature the yield and stereoselectivity are higher.

[0026] The present invention uses benzothiophenone imine and 4-aminoindole as raw materials, and a specific C7 asymmetric Friedel-Crafts alkylation reaction occurs under the catalysis of chiral phosphoric acid to construct C7-functionalized 4-aminoindole compounds containing benzothiophene substructures with high stereoselectivity. It is worth noting that the compounds simultaneously assemble two pharmacodynamic functional groups, benzothiophene and indole substructures. The technology can not only provide new ideas and methods for the synthesis of such compounds, but also greatly enrich the types of such compounds and provide more candidate molecules for new drug screening.

[0027] The third object of the present invention is to provide the use of the chiral C7-functionalized 4-aminoindole compounds in the preparation of anti-cancer drugs.

[0028] In addition, the application value of the compounds of the present invention also lies in that many existing indole compounds and benzothiophene compounds have good biological activity, so it can be reasonably predicted that the new large class of compounds provided by the present invention also has certain biological activity, thereby providing a sufficient source of compounds for screening drug activity; in addition, it can provide more candidate molecules for the development of new drugs and drug screening, especially high-throughput screening, enriching the library of such compounds. In addition, the present invention provides a synthetic method with mild conditions, simple operation and low catalyst dosage to obtain a series of 4-aminoindole compounds containing chiral C7-functionalization.

[0029] The advantages of the present invention are: the present invention uses benzothiophene imine and 4-aminoindole as raw materials, and a specific C7-position asymmetric Friedel-Crafts alkylation reaction occurs under the catalysis of chiral phosphoric acid, and a series of C7-functionalized 4-aminoindole compounds with diverse structures containing benzothiophene substructures are prepared with high yield and high enantioselectivity. The compound contains benzothiophene and indole substructures, and can provide more candidate molecules for the research and development of new drugs and the screening of drugs, especially high-throughput screening, and enrich the library of such compounds; at the same time, through cell experiments, it is shown that the synthesized chiral C7-functionalized 4-aminoindole compounds have good anti-cancer activity; the method of the present invention has the advantages of mild reaction conditions, low catalyst dosage, simple operation, very good stereoselectivity, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 is the hydrogen spectrum of Ig prepared in Example 7;

[0031] Figure 2 is the carbon spectrum of Ig obtained in Example 7;

[0032] Figure 3 This is a single crystal image of Ig prepared in Example 7. DETAILED DESCRIPTION

[0033] The present invention will be further described below in conjunction with embodiments.

[0034] Example 1: Synthesis of Compound Ia

[0035]

[0036] A catalytic amount of chiral phosphoric acid CPA, benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and solvent (1 mL) were added to a dry reaction tube in sequence. The reaction mixture was then stirred at a specific temperature for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ia, as follows:

[0037]

[0038] Table 1 Different reaction conditions

[0039] Serial number CPA Solvents x Temperature(℃) Time (min) Yield (%) ee(%) 1 CPA-1 <![CDATA[CH2Cl2]]> 10 30 30 85 78 2 CPA-2 <![CDATA[CH2Cl2]]> 10 30 30 79 70 3 CPA-3 <![CDATA[CH2Cl2]]> 10 30 30 88 60 4 CPA-4 <![CDATA[CH2Cl2]]> 10 30 30 84 98 5 CPA-5 <![CDATA[CH2Cl2]]> 10 30 30 89 98 6 CPA-5 <![CDATA[CHCl3]]> 10 30 20 88 97 7 CPA-5 toluene 10 30 15 90 98 8 CPA-5 Xylene 10 30 15 80 97 9 CPA-5 PhCl 10 30 15 89 98 10 CPA-5 toluene 5 30 20 92 98 11 CPA-5 toluene 1 30 30 97 98 12 CPA-5 toluene 0.5 30 30 96 97 13 CPA-5 toluene 0.5 0 60 97 >99

[0040] As can be seen from Table 1, by investigating different chiral phosphoric acids CPA, solvent catalyst dosage and temperature, 0.5 mol% CPA-5 was finally used as a catalyst, toluene was used as a solvent, and the reaction temperature was 0°C, which was a more preferred scheme. Under the optimal scheme, the yield, enantioselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ia obtained are as follows: 97% yield, >99% ee; [α]D 20 =+391.46 (c 1.058, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =20.444min,t minor =14.785min; 1 H NMR (400MHz, CDCl3): δ9.96(s,1H),7.79(dd,J=8.2,2.3Hz,1H),7.43(s,1H),7.38–7.27(m,5H),7.27–7.20(m,2H),7.18(d,J=3 .5Hz,1H),6.44(d,J=3.5Hz,1H),6.10(dd,J=8.4,2.3Hz,1H),5.51(s,1H),4.52(s,1H),4.42(s,2H),2.25(s,3H),1.38(s,9H); 13 CNMR (101MHz, CDCl3): δ197.4,153.7,146.8,143.1,139.4,137.2,135.0,133.7,128.7,128.2,127.9,127.5,1 27.4,124.1,124.0,123.5,122.9,118.0,106.9,99.0,98.7,81.4,79.7,48.0,28.2,20.8; HRMS(ESI)Calcd.for C 29 H 30 N3O3S[M+H] + 500.2002, found: 500.2008;

[0041] Scale-up experiment: CPA-5 (0.075 mmol), benzothiophene imine II-a (3 mmol), 4-aminoindole (III-a) (2.5 mmol) and toluene solvent (25 mL) were added in sequence into a dry reaction tube, and the reaction mixture was stirred at 0°C for 40 minutes. After the reaction was complete, the crude product was separated and purified by column chromatography to obtain 1.2 g of compound Ia with a yield of 94% and 97% ee.

[0042] Example 2: Synthesis of Compound Ib

[0043]

[0044] CPA-5 (0.005 mmol), benzothiophene imine II-b (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ib;

[0045] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ib obtained are as follows: 98% yield, 99% ee; [α] D 20 =+427.28 (c 1.245, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =15.174min,t minor =12.772min; 1 H NMR (400MHz, CDCl3): δ9.91(s,1H),7.74(d,J=8.3Hz,1H),7.40(d,J=1.9Hz,1H),7.34–7.21(m,5H),7.21–7.15(m,2H),7.12(t,J=2.9Hz,1H), 6.37(dd,J=3.3,2.1Hz,1H),6.04(d,J=8.3Hz,1H),5.43(s,1H),4.60–4.19(m,3H),2.49(q,J=7.6Hz,2H),1.33(s,9H),1.08(t,J=7.6Hz,3H); 13 CNMR (101MHz, CDCl3): δ197.5,153.7,147.1,143.1,141.4,139.4,136.3,133.7,128.8,127.9,127.6,127.4,1 27.1,124.1,123.6,122.9,118.0,106.9,99.0,98.7,81.4,79.7,48.0,29.8,28.3,15.4; HRMS(ESI):Calcd.for C 30 H 32 N3O3S[M+H] + 514.2159,found:514.2165.

[0046] Example 3: Synthesis of Compound Ic

[0047]

[0048] CPA-5 (0.005 mmol), benzothiophene imine II-c (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Ic;

[0049] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ic obtained are as follows: 90% yield, 97% ee; [α] D 20 =+460.00 (c 1.110, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =17.603min,t minor =15.981min; 1 H NMR (400MHz, CDCl3): δ9.91 (s, 1H), 7.74 (d, J = 8.3Hz, 1H), 7.43 (s, 1H), 7.2 8(d,J=8.0Hz,3H),7.22(t,J=7.3Hz,2H),7.19–7.13(m,2H),7.11(d,J=3.1 Hz,1H),6.37(d,J=3.5Hz,1H),6.04(d,J=8.3Hz,1H),5.42(s,1H),4.52(s, 1H), 4.35 (s, 2H), 2.74 (p, J = 7.0Hz, 1H), 1.32 (s, 9H), 1.08 (t, J = 6.3Hz, 6H); 13 C NMR (101MHz, CDCl3): δ197.5,153.7,147.2,146.1,143.0,139.2,135.2,133.7,128.8,127.9,127.6,127.4,12 5.7,124.0,123.6,123.0,118.1,107.0,99.2,98.7,81.6,79.7,48.1,33.6,23.9,23.8.HRMS(ESI):Calcd.forC 31 H 34 N3O3S[M+H] + 528.2315,found:528.2315.

[0050] Example 4: Synthesis of Compound Id

[0051]

[0052] CPA-5 (0.005 mmol), benzothiophene imine II-d (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Id;

[0053] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of the obtained Id are as follows: 81% yield; 99% ee; [α] D 20 =+261.45 (c 0.230, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =10.052min,t minor =9.220min; 1 H NMR (400MHz, CDCl3): δ10.01(s,1H),7.83(d,J=8.3Hz,1H),7.65(d,J=2.1Hz,1H),7.54(dd,J=8.4,2.1Hz,1H),7.36(d,J=7.2Hz,2H),7.34–7. 23(m,4H),7.21(t,J=2.9Hz,1H),6.45(dd,J=3.4,2.1Hz,1H),6.11(d,J =8.3Hz,1H),5.50(s,1H),4.62–4.36(m,3H),1.40(s,9H),1.24(s,9H); 13 CNMR (101MHz, CDCl3): δ197.6,153.7,148.5,143.2,139.3,134.0,133.7,128.8,127.6,127.4,124.8,124.1,1 23.6,123.5,122.9,118.0,116.0,106.9,99.0,98.7,81.4,79.8,48.0,34.6,31.2,28.3; HRMS(ESI):Calcd.for C 32 H 36 N3O3S[M+H] + 542.2472,found:542.2479.

[0054] Example 5: Synthesis of Compound Ie

[0055]

[0056] CPA-5 (0.005 mmol), benzothiophene imine II-e (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Ie;

[0057] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ie obtained are as follows: 88% yield, 95% ee; [α] D 20 =+393.30 (c 1.110, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =20.207min,t minor =17.478min; 1 H NMR (400MHz, CDCl3): δ9.86 (s, 1H), 7.68 (d, J = 8.3Hz, 1H), 7.53 (t, J = 7.1Hz, 1H), 7.22 (m, 5H), 7.09 (d, J = 3.2Hz, 1H), 6.95 (d, J = 8. 5Hz,1H),6.71(t,J=8.7Hz,1H),6.36(d,J=3.3Hz,1H),6.04(d,J=8.3Hz,1H),5.48(s,1H),4.56(s,1H),4.35(s,2H),1.34(s,9H); 13 CNMR (101MHz, CDCl3): δ195.5,167.8(d,J=260.6Hz),153.6,143.3,139.3,133.6,130.45(d,J=11.1Hz),128.8,127.5,127.4,124.35( d,J=2.0Hz),124.0,123.6,123.0,118.0,116.0,113.3(d,J=23.2Hz),106.4,99.0,98.7,81.7,80.1,48.0,28.3; HRMS(ESI):Calcd.for C 28 H 27 FN3O3S[M+H] + 504.1752,found:504.1744.

[0058] Example 6: Synthesis of Compound If

[0059]

[0060] CPA-5 (0.005 mmol), benzothiophene imine II-f (0.12 mmol), 4-aminoindole (III-a) (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound If;

[0061] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of If obtained are as follows: 99% yield, >99% ee; [α] D 20 =+518.25 (c 0.537, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =36.396min,t minor =24.152min; 1 H NMR (400MHz, CDCl3) δ9.96 (s, 1H), 7.74 (d, J = 8.3Hz, 1H), 6.45 (t, J = 2.6Hz, 1H ),6.11(d,J=8.3Hz,1H),5.55(s,1H),4.55(s,1H),4.44(s,2H),1.40(s,9H); 13 C NMR (101MHz, CDCl3) δ194.8,153.6,143.3,139.3,135.8,133.5,130.6,128.8,127.5,127.4,124.0,123 .9,123.6,123.1,123.0,118.1,116.0,106.3,98.9,98.7,81.8,79.5,48.0,28.2; HRMS(ESI)Calcd.for C 28 H 27 BrN3O3S[M+H] + 566.0934,found:566.0941.

[0062] Example 7: Synthesis of Compound Ig

[0063]

[0064] CPA-5 (0.005 mmol), benzothiophene imine II-g (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ig;

[0065] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of the obtained Ig are as follows: 99% yield, 98% ee; [α] D 20 =+462.70 (c 1.403, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =15.801min,t minor =12.280min; 1 H NMR (400MHz, CDCl3): δ9.90(s,1H),7.71(d,J=8.2Hz,1H),7.41(d,J=7.7Hz,1H),7.32–7.20(m,5H),7.17(t,J=5.9Hz,1H),7.11(d,J=3.1Hz ,1H),6.96(t,J=7.6Hz,1H),6.36(d,J=3.5Hz,1H),6.03(d,J=8.3Hz,1H),5.45(s,1H),4.45(s,1H),4.36(s,2H),2.26(s,3H),1.29(s,9H); 13 C NMR (101MHz, CDCl3): δ197.8,153.7,149.6,143.1,139.4,136.2,133.7,132.7,128.7,127.7,127.5,127.4 ,125.6,125.2,123.9,122.9,118.0,107.0,98.9,98.7,81.6,79.5,48.0,28.2,19.0; HRMS(ESI):Calcd.for C 29 H 30 N3O3S[M+H] + 500.2002, found: 500.2005; the above hydrogen spectrum and carbon spectrum are as follows Figure 1 and Figure 2 As shown;

[0066] Single crystal diffraction experiment:

[0067] Single crystal cultivation: The main component compound Ig (40 mg) obtained in Example 7 was dissolved in a mixture of 20 mL of dichloromethane and ethanol and allowed to stand at room temperature for 7 days. Single crystals precipitated and were collected for single crystal diffraction test.

[0068] The test parameters are shown in Table 2:

[0069] Table 2 Single crystal test parameters

[0070]

[0071]

[0072] The results of the test are as follows Figure 3 As shown, the structure of compound Ig was determined by the above spectrum and data.

[0073] Example 8: Synthesis of Compound Ih

[0074]

[0075] CPA-5 (0.005 mmol), benzothiophene imine II-h (0.12 mmol), 4-aminoindole (III-a) (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Ih;

[0076] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ih obtained are as follows: 93% yield, >99% ee; [α] D 20 =+481.17 (c 1.195, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =8.862min,t minor =10.680min; 1H NMR (400MHz, CDCl3): δ9.98 (s, 1H), 7.69 (d, J = 8.2Hz, 1H), 7.30 (d, J = 7.5Hz, 2H), 7.23(t,J=7.5Hz,2H),7.18(d,J=8.0Hz,1H),7.14(d,J=3.1Hz,1H),7.08(d,J=7.6 Hz,1H),6.72(d,J=7.5Hz,1H),6.39(s,1H),6.07(d,J=8.2Hz,1H),5.41(s,1H),4. 88–4.40(m,1H),4.54(s,1H),4.37(s,2H),2.38(s,3H),2.23(s,3H),1.29(s,9H); 13 C NMR (101MHz, CDCl3): δ198.8,153.8,150.1,140.0,135.3,133.8,130.0,128.8,127.7,127.6,12 7.4,124.8,123.7,123.0,118.2,98.6,81.6,78.1,48.3,28.3,18.8,18.6; HRMS(ESI):Calcd.for C 30 H 32 N3O3S[M+H] + 514.2159,found:514.2162.

[0077] Example 9: Synthesis of Compound Ii

[0078]

[0079] CPA-5 (0.005 mmol), benzothiophene imine II-i (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C. After the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ii;

[0080] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ii obtained are as follows: 86% yield, 99% ee; [α] D 20 =+462.48 (c 1.043, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =17.445min,t minor =10.585min;1 H NMR(400MHz, CDCl3)δ10.06(s,1H),7.77(d,J=8.1Hz,1H),7.34–7.23(m,4H),7.21–7.06(m,4H ),6.74(s,1H),6.61(s,1H),5.55(s,1H),4.46(s,2H),2.31(s,3H),2.24(s,3H),1.36(s,9H); 13 C NMR (101MHz, CDCl3): δ197.8,153.7,146.4,138.0,135.4,134.2,132.6,129.5,128.6,128.4,127.4,12 5.6,125.1,125.0,124.0,123.3,122.7,99.7,81.8,79.3,52.0,28.2,20.7,18.8; HRMS(ESI):Calcd.for C 30 H 32 N3O3S[M+H] + 514.2159,found:514.2162.

[0081] Example 10: Synthesis of Compound Ij

[0082]

[0083] CPA-5 (0.005 mmol), benzothiophene imine II-j (0.12 mmol), 4-aminoindole III-a (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Ij;

[0084] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ij obtained are as follows: 90% yield,>99%ee; [α] D 20 =+490.10 (c 0.970, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =17.776min,t minor =15.930min; 1H NMR (400MHz, CDCl3): δ9.96(s,1H),7.80(d,J=8.2Hz,1H),7.62(d,J=7.7Hz,1H),7.46(t,J=7.7Hz,1H),7.40–7.21(m,6H),7.18(d,J=3 .0Hz,1H),7.09(t,J=7.5Hz,1H),6.43(d,J=3.3Hz,1H),6.11(d,J=8.2Hz,1H),5.52(s,1H),4.47(d,J=37.3Hz,3H),1.55–1.15(m,10H); 13 CNMR (101MHz, CDCl3): δ197.3,153.7,150.0,143.2,139.3,136.0,133.7,128.8,128.2,127.9,127.5,12 7.4,125.0,124.0,123.8,122.9,118.0,106.7,99.0,98.7,81.6,79.4,48.0,28.2; HRMS(ESI):Calcd.for C 28 H 28 N3O3S[M+H] + 534.1613,found:534.1619.

[0085] Example 11: Synthesis of Compound Ik

[0086]

[0087] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-b (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Ik;

[0088] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ik obtained are as follows: 97% yield, 98% ee; [α] D 20 =+320.17 (c 1.238, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =18.874min,t minor =13.884min; 1H NMR (400MHz, CDCl3): δ9.90(s,1H),7.70(dd,J=8.3,1.7Hz,1H),7.36(s,1H),7.27(ddt,J=7.5,3.7,1.7Hz,2H),7.21(d,J=8.3Hz,1H),7.18–7.11(m ,2H),7.10–7.01(m,2H),6.40(dt,J=3.7,1.9Hz,1H),5.96(dd,J=8.3,1.7 Hz,1H),5.44(s,1H),4.68(s,1H),4.45(s,2H),2.17(s,3H),1.30(s,9H); 13 CNMR (101MHz, CDCl3): δ197.4,153.6,146.8,142.4,137.2,136.4,134.9,133.7,133.2,129.5,128.9,128.4,128.2 ,127.8,126.9,123.9,123.4,122.9,118.1,107.2,99.2,98.6,81.6,79.5,45.6,28.2,20.7; HRMS(ESI):Calcd.forC 29 H 29 ClN3O3S[M+H] + 486.1846,found:486.1849.

[0089] Example 12: Synthesis of Compound I1

[0090]

[0091] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-c (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Il;

[0092] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Il obtained are as follows: 99% yield, 99% yield, 99% ee; [α] D 20 =+352.53 (c 1.413, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =25.122min,t minor=16.947min; 1 HNMR (400MHz, CDCl3): δ9.89(s,1H),7.69(d,J=8.2Hz,1H),7.35(d,J=1.9Hz,1H),7.33–7.29(m,2H),7.21(dd,J=8.1,2.0Hz,1H),7.15(d,J=4.1Hz,1 H),7.11(dd,J=8.3,2.3Hz,3H),6.36(dd,J=3.3,2.1Hz,1H),5.94(d,J=8. 3Hz,1H),5.44(s,1H),4.55(s,1H),4.29(s,2H),2.17(s,3H),1.30(s,9H); 13 C NMR (101MHz, CDCl3): δ197.4,153.7,146.8,142.5,138.3,137.3,135.0,133.7,131.8,129.1,128.2,127.8, 123.9,123.5,123.1,121.0,118.1,107.3,99.3,98.6,81.8,79.6,47.4,28.2,20.8; HRMS(ESI):Calcd.forC 29 H 29 BrN3O3S[M+H] + 578.1108,found:578.1118.

[0093] Example 13: Synthesis of Compound Im

[0094]

[0095] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-d (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Im;

[0096] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of the obtained Im are as follows: 92% yield, 97% ee; [α] D 20 =+572.27 (c 1.020, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =22.713min,tminor =14.223min; 1 H NMR (400MHz, CDCl3): δ9.89 (s, 1H), 7.76 (d, J = 8.2Hz, 1H), 7.38 (s, 1H), 7.24 (dd,J=8.0,1.9Hz,1H),7.18(d,J=1.9Hz,1H),7.13(t,J=2.9Hz,1H),6.43(t ,J=2.7Hz,1H),6.10(d,J=8.2Hz,1H),5.43(s,1H),3.10–2.91(m,2H),2.19( s,3H),1.31(s,9H),1.09–1.04(m,1H),0.53–0.43(m,2H),0.25–0.13(m,2H); 13 C NMR (101MHz, CDCl3): δ197.4,153.7,146.8,137.2,135.0,133.8,128.3,127.9,123.9,123.6, 123.0,118.3,98.8,79.7,49.3,31.8,29.8,28.3,20.8,10.8,3.7,1.1; HRMS(ESI):Calcd.for C 26 H 30 N3O3S[M+H] + 464.2002,found:464.2009.

[0097] Example 14: Synthesis of Compound In

[0098]

[0099] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-e (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound In;

[0100] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of In obtained are as follows: 96% yield, 96% ee; [α] D 20 =+479.62 (c 0.988, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =19.742min,t minor=12.346min; 1 H NMR (400MHz, CDCl3): δ9.86 (s, 1H), 7.74 (d, J = 8.2Hz, 1H), 7.35 (s, 1H), 7.22 (dd, J = 8 .1,1.9Hz,1H),7.19–7.13(m,1H),7.09(t,J=2.8Hz,1H),6.35(dd,J=3.3,2.1Hz,1H) ,6.02(d,J=8.3Hz,1H),5.46(s,1H),4.20(s,1H),3.02–2.85(m,2H),2.18(s,3H),1. 86(dt,J=13.4,6.7Hz,1H),1.31(s,9H),0.91(d,J=1.9Hz,3H),0.89(d,J=1.9Hz,3H); 13 C NMR (101MHz, CDCl3): δ197.4,153.7,146.8,143.4,137.2,134.9,133.7,128.2,127.9,124.0,123. 5,122.7,117.9,106.2,98.5,81.4,79.7,60.5,51.6,28.2,28.1,20.8,20.6; HRMS(ESI):Calcd.for C 26 H 32 N3O3S[M+H] + 466.2159,found:466.2163.

[0101] Example 15: Synthesis of Compound Io

[0102]

[0103] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole (III-f) (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was completed, the crude product was separated and purified by column chromatography to obtain compound Io;

[0104] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Io obtained are as follows: 95% yield, 96% ee; [α] D 20 =+480.89 (c 1.055, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major=17.704min,t minor =11.239min; 1 H NMR (400MHz, CDCl3): δ9.86 (s, 1H), 7.75 (dd, J = 8.3, 2.8Hz, 1H), 7.36 (s, 1H), 7.25–7.19 (m, 1 H),7.16(d,J=8.0Hz,1H),7.08(d,J=3.0Hz,1H),6.34(q,J=2.6Hz,1H),6.03(t,J=9.0Hz,1H), 5.46(s,1H),4.13(s,1H),3.13(td,J=7.1,2.9Hz,1H),2.95(d,J=6.9Hz,1H),2.18(s,3H),1.8 6(dt,J=13.4,6.7Hz,1H),1.57(p,J=7.2Hz,1H),1.31(s,9H),0.97–0.86(m,4H),0.86(s,1H); 13 C NMR (101MHz, CDCl3): δ197.4,153.7,146.8,143.5,137.2,134.9,133.7,128.2,127.9,124.0,123.5,122.7,1 22.7,118.0,117.9,106.1,98.5,81.5,79.7,51.5,43.5,31.7,28.2,20.8,20.6,14.0; HRMS(ESI):Calcd.for C 26 H 32 N3O3S[M+H] + 466.2159,found:466.2165.

[0105] Example 16: Synthesis of Compound Ip

[0106]

[0107] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-g (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ip;

[0108] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Ip obtained are as follows: 96% yield, 93% ee; [α] D 20=+368.59 (c 0.965, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =17.473min,t minor =12.008min; 1 H NMR (400MHz, CDCl3): δ9.89 (s, 1H), 7.76 (d, J = 8.3Hz, 1H), 7.38 (d, J = 1.8Hz, 1H), 7.24 (dd, J =8.1,1.9Hz,1H),7.18(d,J=1.4Hz,1H),7.12(t,J=2.9Hz,1H),6.38(t,J=2.7Hz,1H),6.08( d,J=8.3Hz,1H),5.90(ddt,J=17.2,10.5,5.4Hz,1H),5.43(s,1H),5.20(dq,J=17.2,1.7Hz, 1H),5.08(dq,J=10.3,1.6Hz,1H),4.44(s,1H),3.87–3.67(m,2H),2.19(s,3H),1.31(s,9H); 13 C NMR (101MHz, CDCl3): δ197.4,153.7,146.9,142.8,137.2,135.2,135.0,133.8,128.3,127.9,123.9 ,123.5,123.0,118.3,116.6,107.1,99.3,98.6,81.4,79.7,46.5,28.3,20.8; HRMS(ESI):Calcd.for C 25 H 28 N3O3S[M+H] + 450.1846,found:450.1852.

[0109] Example 17: Synthesis of Compound Iq

[0110]

[0111] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-h (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Iq;

[0112] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Iq obtained are as follows: 99% yield, 91% ee; [α] D 20 =+370.98 (c 1.098, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =21.997min,t minor =15.683min; 1 H NMR (400MHz, CDCl3): δ9.91(s,1H),7.81(d,J=8.2Hz,1H),7.38(s,1H),7.25(dd,J=8.0,1.9Hz,1H),7.18(d,J=3.7Hz,1H),7.13(t,J=2.9Hz,1H),6 .37(dd,J=3.3,2.1Hz,1H),6.17(d,J=8.2Hz,1H),5.45(s,1H),4.38(s,1H ),3.96(d,J=2.4Hz,2H),2.19(s,3H),2.13(t,J=2.4Hz,1H),1.31(s,9H); 13 C NMR (101MHz, CDCl3): δ197.5,153.7,146.8,141.7,137.3,135.1,133.7,128.3,127.9,123.7,123. 6,123.3,118.7,108.3,99.8,98.6,81.5,80.9,79.6,71.6,33.5,28.2,20.8; HRMS(ESI):Calcd.for C 25 H 26 N3O3S[M+H] + 448.1689,found:448.1694.

[0113] Example 18: Synthesis of Compound Ir

[0114]

[0115] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole (III-i) (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction; after the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Ir;

[0116] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of the obtained Ir are as follows: 85% yield, 94% ee; [α] D 20 =+389.92 (c 1.128, DCM); HPLC: Chiralpak IC column; hexane / EtOH = 80 / 20; flow rate: 1.0mL / min; λ = 254nm; t major =4.958min,t minor =6.085min; 1 H NMR (400MHz, CDCl3) δ9.92 (s, 1H), 7.73 (d, J = 8.4Hz, 1H), 7.37 (d, J = 1.8Hz, 1H), 7.23 (dd, J=8.2,1.9Hz,1H),7.16(d,J=8.1Hz,1H),7.10(t,J=2.9Hz,1H),6.54(t,J=2.7Hz,1H),6.2 6(d,J=8.4Hz,1H),5.81(ddt,J=17.2,10.3,5.1Hz,2H),5.46(s,1H),5.17(dq,J=17.2,1. 8Hz,2H),5.10(dt,J=10.3,1.7Hz,2H),4.02–3.77(m,4H),2.18(s,3H),1.44–1.12(m,9H); 13 CNMR (101MHz, CDCl3) δ197.4,153.7,146.8,146.3,137.3,135.0,134.8,128.2,127.9,123.5,123 .2,122.8,120.6,116.8,108.4,105.3,102.3,81.5,79.6,53.8,28.2,20.8; HRMS(ESI)Calcd.for C 28 H 32 N3O3S[M+H] + 490.2159,found:490.2165.

[0117] Example 19: Synthesis of Compound Is

[0118]

[0119] CPA-5 (0.005 mmol), benzothiophene imine II-a (0.12 mmol), 4-aminoindole III-j (0.1 mmol) and toluene solvent (1 mL) were added in sequence to a dry reaction tube, and the reaction mixture was stirred at 0°C for reaction. After the reaction was complete, the crude product was separated and purified by column chromatography to obtain compound Is;

[0120] The yield, stereoselectivity, optical rotation, hydrogen spectrum, carbon spectrum and mass spectrum data of Is obtained are as follows: 99% yield, 91% ee; [α] D 20 =+346.83 (c 0.783, DCM); HPLC: Chiralpak IA column; hexane / EtOH = 70 / 30; flow rate: 1.0mL / min; λ = 254nm; t major =11.798min,t minor =15.189min; 1 H NMR (400MHz, CDCl3): δ9.95(s,1H),7.79(d,J=8.2Hz,1H),7.38(s,1H),7.25(dd,J=8.1,1.9Hz,1H),7.17(dd, J=5.8,2.7Hz,2H),6.63–6.50(m,2H),5.51(s,1H),4.09(d,J=2.4Hz,4H),2.19(d,J=2.9Hz,5H),1.30(s,9H); 13 C NMR (101MHz, CDCl3): δ197.5,153.7,146.8,144.5,137.5,135.2,134.4,128.2,127.7,123.9,123 .6,122.8,122.6,112.1,107.6,101.3,81.8,79.4,73.3,41.1,28.2,20.8; HRMS(ESI):Calcd.for C 28 H 28 N3O3S[M+H] + 486.1846,found:486.1853.

[0121] Embodiment 20

[0122] Activity test of the compounds prepared in Examples 1-19

[0123] Specific experimental procedures: Leukemia cells K562 were used to evaluate the anticancer activity of chiral C7-functionalized 4-aminoindole compounds containing benzothiophene substructures by MTT assay. 5000 human leukemia cells K562 were inoculated into a 96-well cell culture plate and allowed to grow for 24 hours. Then, a certain concentration of the compounds synthesized in Examples 1-19 above was added, and the anti-tumor drug cisplatin was used as a control for 48 hours. Then, the average 50% inhibition concentration (IC 50 Each concentration was repeated at least 3 times, and all experiments were repeated 3 times. The average results are shown in Table 3.

[0124] Table 3 Cell activity assay results

[0125] Compound Ia Ib Ic Id Ie If Ig Ih Ii Ij <![CDATA[IC 50 (uM)]]> 45.2 37.6 22.5 56.7 19.3 26.7 29.3 44.5 33.7 38.9 Compound I I-l Im In Io Ip Iq I-r Is Cisplatin <![CDATA[IC 50 (uM)]]> 40.3 53.2 21.5 26.6 35.4 31.2 29.6 20.4 27.9 21.7

[0126] It can be seen from Table 1 that the compounds of Examples 1-19 of the present invention all have anti-K562 activities to varying degrees.

[0127] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A chiral C7-functionalized 4-aminoindole compound, characterized in that: It has the structure shown in the following structural formula: In the above structural formula, R 1 The group is a single or multiple substituent, and the substituent is selected from hydrogen, alkyl, alkoxy or halogen; R 2 and R 3 The radicals are independently selected from any one of hydrogen, alkyl, allyl or propargyl.

2. A method for preparing the chiral C7-functionalized 4-aminoindole compound according to claim 1, characterized in that: Dissolve benzothiophene ketimine (II) and 4-aminoindole (III) in an organic solvent, then add a chiral catalyst, stir and react at 0°C to 30°C, and after the reaction is completed, separate and purify to obtain a product (I), wherein: The benzothiophenone imine (II) has the following structure: The 4-aminoindole (III) has the following structure:

3. The preparation method according to claim 2, characterized in that: The organic solvent is selected from one or a mixture of toluene, mesitylene, dichloromethane, chloroform, tetrahydrofuran, ether, acetonitrile, ethanol, methanol, 1,4-dioxane, and chlorobenzene.

4. The preparation method according to claim 2, characterized in that: The chiral catalyst is a chiral phosphoric acid catalyst.

5. The method according to claim 4, characterized in that The chiral phosphoric acid catalyst is selected from CPA-1, CPA-2, CPA-3, CPA-4 or CPA-5, and has the following structure:

6. The method according to claim 5, characterized in that The chiral phosphoric acid catalyst is CPA-5.

7. The preparation method according to claim 2, characterized in that: The amount of the chiral catalyst used is 0.5% to 10% of the molar amount of benzothiophenone imine (II).

8. Use of the chiral C7-functionalized 4-aminoindole compound according to claim 1 in the preparation of anti-cancer drugs.

Citation Information

Patent Citations

  • Chiral 3-substituted isoindolinone compounds, and preparation method and application thereof

    CN106986810A

  • Chiral 3-indolyl-3,3'-disubstituted oxoindole compound and preparation method thereof

    CN111646931A

  • Propargyl-substituted chiral 3-amino-3, 3-disubstituted oxoindole compound as well as synthesis method and application of propargyl-substituted chiral 3-amino-3, 3-disubstituted oxoindole compound

    CN115215783A

  • Chiral 2-(beta-amino) pyridine derivative as well as preparation method and application thereof

    CN117865937A